Editing Dextrorphan (section)

===Pharmacodynamics===
{| class="wikitable floatleft" style="font-size:small;"
|+ Dextrorphan<ref name="PDSP">{{cite web | title = PDSP K<sub>i</sub> Database | work = Psychoactive Drug Screening Program (PDSP)|author1-link=Bryan Roth| vauthors = Roth BL, Driscol J | publisher = University of North Carolina at Chapel Hill and the United States National Institute of Mental Health | access-date = 14 August 2017 | url = https://pdsp.unc.edu/databases/pdsp.php?knowID=0&kiKey=&receptorDD=&receptor=&speciesDD=&species=&sourcesDD=&source=&hotLigandDD=&hotLigand=&testLigandDD=&testFreeRadio=testFreeRadio&testLigand=dextrorphan&referenceDD=&reference=&KiGreater=&KiLess=&kiAllRadio=all&doQuery=Submit+Query}}</ref><ref name="pmid26826604">{{cite journal | vauthors = Nguyen L, Thomas KL, Lucke-Wold BP, Cavendish JZ, Crowe MS, Matsumoto RR | title = Dextromethorphan: An update on its utility for neurological and neuropsychiatric disorders | journal = Pharmacol. Ther. | volume = 159 | pages = 1–22 | year = 2016 | pmid = 26826604 | doi = 10.1016/j.pharmthera.2016.01.016 }}</ref><ref name="pmid17689532">{{cite journal | vauthors = Werling LL, Keller A, Frank JG, Nuwayhid SJ | title = A comparison of the binding profiles of dextromethorphan, memantine, fluoxetine and amitriptyline: treatment of involuntary emotional expression disorder | journal = Exp. Neurol. | volume = 207 | issue = 2 | pages = 248–57 | year = 2007 | pmid = 17689532 | doi = 10.1016/j.expneurol.2007.06.013 | s2cid = 38476281 }}</ref><ref name="pmid27139517">{{cite journal | vauthors = Taylor CP, Traynelis SF, Siffert J, Pope LE, Matsumoto RR | title = Pharmacology of dextromethorphan: Relevance to dextromethorphan/quinidine (Nuedexta®) clinical use | journal = Pharmacol. Ther. | volume = 164 | pages = 170–82 | year = 2016 | pmid = 27139517 | doi = 10.1016/j.pharmthera.2016.04.010 | doi-access = free }}</ref>
|-
! Site !! K<sub>i</sub> (nM) !! Species !! Ref
|-
| [[NMDA receptor|{{abbr|NMDAR|N-Methyl-D-aspartate receptor}}<br />(MK-801)]] || 486–906 || Rat || <ref name="pmid26826604" />
|-
| [[Sigma-1 receptor|σ<sub>1</sub>]] || 118–481 || Rat || <ref name="pmid26826604" />
|-
| [[Sigma-2 receptor|σ<sub>2</sub>]] || 11,325–15,582 || Rat || <ref name="pmid26826604" />
|-
| {{abbrlink|MOR|μ-Opioid receptor}} || 420<br />&gt;1,000 || Rat<br />Human || <ref name="pmid26826604" /><ref name="pmid7815359">{{cite journal | vauthors = Raynor K, Kong H, Mestek A, Bye LS, Tian M, Liu J, Yu L, Reisine T | title = Characterization of the cloned human mu opioid receptor | journal = J. Pharmacol. Exp. Ther. | volume = 272 | issue = 1 | pages = 423–8 | year = 1995 | pmid = 7815359 }}</ref>
|-
| {{abbrlink|DOR|δ-Opioid receptor}} || 34,700 || Rat || <ref name="pmid26826604" />
|-
| {{abbrlink|KOR|κ-Opioid receptor}} || 5,950 || Rat || <ref name="pmid26826604" />
|-
| {{abbrlink|SERT|Serotonin transporter}} || 401–484 || Rat || <ref name="pmid26826604" />
|-
| {{abbrlink|NET|Norepinephrine transporter}} || ≥340 || Rat || <ref name="pmid26826604" />
|-
| {{abbrlink|DAT|Dopamine transporter}} || >1,000 || Rat || <ref name="pmid26826604" />
|-
| [[5-HT1A receptor|5-HT<sub>1A</sub>]] || >1,000 || Rat || <ref name="pmid26826604" />
|-
| [[5-HT1B receptor|5-HT<sub>1B</sub>]]<sub>/</sub>[[5-HT1D receptor|<sub>1D</sub>]] || 54% at 1&nbsp;μM || Rat || <ref name="pmid26826604" />
|-
| [[5-HT2A receptor|5-HT<sub>2A</sub>]] || >1,000 || Rat || <ref name="pmid26826604" />
|-
| [[Alpha-1 adrenergic receptor|α<sub>1</sub>]] ||>1,000 || Rat || <ref name="pmid26826604" />
|-
| [[Alpha-2 adrenergic receptor|α<sub>2</sub>]] || >1,000 || Rat || <ref name="pmid26826604" />
|-
| [[Beta-adrenergic receptor|β]] || 35% at 1&nbsp;μM || Rat || <ref name="pmid26826604" />
|-
| [[D2 receptor|D<sub>2</sub>]] || >1,000 || Rat || <ref name="pmid26826604" />
|-
| [[H1 receptor|H<sub>1</sub>]] || 95% at 1&nbsp;μM || Rat || <ref name="pmid26826604" />
|-
| {{abbrlink|mAChRs|Muscarinic acetylcholine receptors}} || 100% at 1&nbsp;μM || Rat || <ref name="pmid26826604" />
|-
| {{abbrlink|nAChRs|Nicotinic acetylcholine receptors}} || 1,300–29,600<br />(IC<sub>50</sub>) || Rat || <ref name="pmid26826604" />
|-
| {{abbrlink|VDSCs|Voltage-dependent sodium channels}} || {{abbr|ND|No data}} || {{abbr|ND|No data}} || {{abbr|ND|No data}}
|- class="sortbottom"
| colspan="4" style="width: 1px;" | Values are K<sub>i</sub> (nM), unless otherwise noted. The smaller the value, the more strongly the drug binds to the site.
|}

The pharmacology of dextrorphan is similar to that of [[dextromethorphan]] (DXM). However, dextrorphan is much more potent as an NMDA receptor antagonist and much less active as a [[serotonin reuptake inhibitor]], but retains DXM's activity as a [[norepinephrine reuptake inhibitor]].<ref>{{cite journal | vauthors = Pechnick RN, Poland RE | title = Comparison of the effects of dextromethorphan, dextrorphan, and levorphanol on the hypothalamo-pituitary-adrenal axis | journal = The Journal of Pharmacology and Experimental Therapeutics | volume = 309 | issue = 2 | pages = 515–522 | date = May 2004 | pmid = 14742749 | doi = 10.1124/jpet.103.060038 | s2cid = 274504 }}</ref>
It also has more affinity for the opioid receptors than dextromethorphan, significantly so at high doses.